Cardiovascular effects of calcium supplements

ResearchSpace/Manakin Repository

Show simple item record

dc.contributor.advisor Reid, I en
dc.contributor.advisor Cornish, J en
dc.contributor.advisor Bolland, M en
dc.contributor.advisor Naot, D en
dc.contributor.advisor Milsom, P en
dc.contributor.author Radford, LT en
dc.date.accessioned 2019-06-05T22:16:05Z en
dc.date.issued 2019 en
dc.identifier.uri http://hdl.handle.net/2292/46868 en
dc.description.abstract Aim: In view of the association of calcium supplements with myocardial infarction and stroke, we sought to understand whether this effect persisted after their discontinuation and whether this risk varied across different patient subgroups. We also sought to understand what effect calcium supplements might exert in a mouse model of accentuated inflammation. Method: We continued follow-up of the Auckland Calcium study participants for a further 5 years to understand the persistence of the harmful effects of calcium supplements in the context of bone protective actions. We re-analysed the Women's Health Initiative Calcium and Vitamin D (WHI CaD) study and performed similar analyses in our pooled, patient-level metaanalysis dataset to detect if calcium supplements conferred a differential cardiovascular risk across various patient groups. Finally, we investigated whether calcium supplements increased vascular calcification, altered the serum mineral profile and produced changes in gene expression of vascular cells in a mouse model of accentuated inflammation. We were also interested as to whether providing calcium over 24 hours would mitigate any negative effects of a single calcium bolus. Findings: Post-trial follow-up of the Auckland Calcium study showed that allocation to calcium reduced forearm and vertebral fractures over the entire follow up period, but did not influence the risk for myocardial infarction, stroke, transient ischaemic attacks, or death. In the bone mineral density sub-study, there were no between-group differences in the percentage change from baseline at any site, at 10 years. Results from the meta-analysis of calcium monotherapy and the re-analysis of the WHI CaD were strikingly similar in terms of risk for myocardial infarction and stroke, however, we found no evidence for an interaction between allocation to calcium and important baseline characteristics. In adiponectin knockout mice, a once daily bolus dose of calcium altered serum mineral profile and genes implicated in vascular calcification. Conclusion: The harmful effects of calcium supplements do not differ across differing patient subgroups and do not persist once discontinued. At the cell level, calcium supplements may play a role in the phenotypic change of vascular smooth muscle cells promoting vascular disease, but this will need to be confirmed in targeted experiments. en
dc.publisher ResearchSpace@Auckland en
dc.relation.ispartof PhD Thesis - University of Auckland en
dc.relation.isreferencedby UoA99265150806502091 en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Cardiovascular effects of calcium supplements en
dc.type Thesis en
thesis.degree.discipline Medicine en
thesis.degree.grantor The University of Auckland en
thesis.degree.level Doctoral en
thesis.degree.name PhD en
dc.rights.holder Copyright: The author en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.elements-id 773846 en
pubs.record-created-at-source-date 2019-06-06 en


Full text options

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Advanced Search

Browse